Transarterial Radioembolization with Yttrium-90 for the Treatment of Hepatocellular Carcinoma

Joseph Ralph Kallini, Ahmed Gabr, Riad Salem, Robert J. Lewandowski*

*Corresponding author for this work

Research output: Contribution to journalReview article

36 Citations (Scopus)

Abstract

Background: Hepatocellular carcinoma (HCC) is a common cause of worldwide mortality. Transarterial radioembolization (TARE) with yttrium-90 (Y90), a transcatheter intra-arterial procedure performed by interventional radiology, has become widely utilized in managing HCC. Methods: The following is a focused review of TARE covering its commercially available products, clinical considerations of treatment, salient clinical trial data establishing its utility, and the current and future roles of TARE in the management of HCC. Results: TARE is indicated for patients with unresectable, intermediate stage HCC. The two available products are glass and resin microspheres. All patients undergoing TARE must be assessed with a history, physical examination, clinical laboratory tests, imaging, and arteriography with macroaggregated albumin. TARE is safe and effective in the treatment of unresectable HCC, as it has a safer toxicity profile than chemoembolization, longer time-to-progression, greater ability to downsize and/or bridge patients to liver transplant, and utility in tumor complicated by portal vein thrombosis. TARE can also serve as an alternative to ablation and chemotherapy. Conclusion: TARE assumes an integral role in the management of unresectable HCC and has been validated by numerous studies.

Original languageEnglish (US)
Pages (from-to)699-714
Number of pages16
JournalAdvances in Therapy
Volume33
Issue number5
DOIs
StatePublished - May 1 2016

Fingerprint

Yttrium
Hepatocellular Carcinoma
Therapeutics
Interventional Radiology
Portal Vein
Microspheres
Physical Examination
Glass
Albumins
Angiography
Thrombosis
History
Clinical Trials
Transplants
Drug Therapy
Mortality
Liver
Neoplasms

Keywords

  • Hepatocellular carcinoma (HCC)
  • Oncology
  • Radioembolization
  • Transarterial radioembolization (TARE)
  • Yttrium-90 (Y90)

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

@article{0f14d213c7654e4b8e2011dd1201dcfb,
title = "Transarterial Radioembolization with Yttrium-90 for the Treatment of Hepatocellular Carcinoma",
abstract = "Background: Hepatocellular carcinoma (HCC) is a common cause of worldwide mortality. Transarterial radioembolization (TARE) with yttrium-90 (Y90), a transcatheter intra-arterial procedure performed by interventional radiology, has become widely utilized in managing HCC. Methods: The following is a focused review of TARE covering its commercially available products, clinical considerations of treatment, salient clinical trial data establishing its utility, and the current and future roles of TARE in the management of HCC. Results: TARE is indicated for patients with unresectable, intermediate stage HCC. The two available products are glass and resin microspheres. All patients undergoing TARE must be assessed with a history, physical examination, clinical laboratory tests, imaging, and arteriography with macroaggregated albumin. TARE is safe and effective in the treatment of unresectable HCC, as it has a safer toxicity profile than chemoembolization, longer time-to-progression, greater ability to downsize and/or bridge patients to liver transplant, and utility in tumor complicated by portal vein thrombosis. TARE can also serve as an alternative to ablation and chemotherapy. Conclusion: TARE assumes an integral role in the management of unresectable HCC and has been validated by numerous studies.",
keywords = "Hepatocellular carcinoma (HCC), Oncology, Radioembolization, Transarterial radioembolization (TARE), Yttrium-90 (Y90)",
author = "Kallini, {Joseph Ralph} and Ahmed Gabr and Riad Salem and Lewandowski, {Robert J.}",
year = "2016",
month = "5",
day = "1",
doi = "10.1007/s12325-016-0324-7",
language = "English (US)",
volume = "33",
pages = "699--714",
journal = "Advances in Therapy",
issn = "0741-238X",
publisher = "Health Communications Inc.",
number = "5",

}

Transarterial Radioembolization with Yttrium-90 for the Treatment of Hepatocellular Carcinoma. / Kallini, Joseph Ralph; Gabr, Ahmed; Salem, Riad; Lewandowski, Robert J.

In: Advances in Therapy, Vol. 33, No. 5, 01.05.2016, p. 699-714.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Transarterial Radioembolization with Yttrium-90 for the Treatment of Hepatocellular Carcinoma

AU - Kallini, Joseph Ralph

AU - Gabr, Ahmed

AU - Salem, Riad

AU - Lewandowski, Robert J.

PY - 2016/5/1

Y1 - 2016/5/1

N2 - Background: Hepatocellular carcinoma (HCC) is a common cause of worldwide mortality. Transarterial radioembolization (TARE) with yttrium-90 (Y90), a transcatheter intra-arterial procedure performed by interventional radiology, has become widely utilized in managing HCC. Methods: The following is a focused review of TARE covering its commercially available products, clinical considerations of treatment, salient clinical trial data establishing its utility, and the current and future roles of TARE in the management of HCC. Results: TARE is indicated for patients with unresectable, intermediate stage HCC. The two available products are glass and resin microspheres. All patients undergoing TARE must be assessed with a history, physical examination, clinical laboratory tests, imaging, and arteriography with macroaggregated albumin. TARE is safe and effective in the treatment of unresectable HCC, as it has a safer toxicity profile than chemoembolization, longer time-to-progression, greater ability to downsize and/or bridge patients to liver transplant, and utility in tumor complicated by portal vein thrombosis. TARE can also serve as an alternative to ablation and chemotherapy. Conclusion: TARE assumes an integral role in the management of unresectable HCC and has been validated by numerous studies.

AB - Background: Hepatocellular carcinoma (HCC) is a common cause of worldwide mortality. Transarterial radioembolization (TARE) with yttrium-90 (Y90), a transcatheter intra-arterial procedure performed by interventional radiology, has become widely utilized in managing HCC. Methods: The following is a focused review of TARE covering its commercially available products, clinical considerations of treatment, salient clinical trial data establishing its utility, and the current and future roles of TARE in the management of HCC. Results: TARE is indicated for patients with unresectable, intermediate stage HCC. The two available products are glass and resin microspheres. All patients undergoing TARE must be assessed with a history, physical examination, clinical laboratory tests, imaging, and arteriography with macroaggregated albumin. TARE is safe and effective in the treatment of unresectable HCC, as it has a safer toxicity profile than chemoembolization, longer time-to-progression, greater ability to downsize and/or bridge patients to liver transplant, and utility in tumor complicated by portal vein thrombosis. TARE can also serve as an alternative to ablation and chemotherapy. Conclusion: TARE assumes an integral role in the management of unresectable HCC and has been validated by numerous studies.

KW - Hepatocellular carcinoma (HCC)

KW - Oncology

KW - Radioembolization

KW - Transarterial radioembolization (TARE)

KW - Yttrium-90 (Y90)

UR - http://www.scopus.com/inward/record.url?scp=84962018325&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84962018325&partnerID=8YFLogxK

U2 - 10.1007/s12325-016-0324-7

DO - 10.1007/s12325-016-0324-7

M3 - Review article

C2 - 27039186

AN - SCOPUS:84962018325

VL - 33

SP - 699

EP - 714

JO - Advances in Therapy

JF - Advances in Therapy

SN - 0741-238X

IS - 5

ER -